DP 13

Drug Profile

DP 13

Alternative Names: DP13

Latest Information Update: 07 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Damian Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Endocrine disorders

Most Recent Events

  • 01 Mar 2017 Phase-I clinical trials in Endocrine disorders (In volunteers) in United Kingdom (PO) (NCT03046589)
  • 15 Feb 2017 Preclinical trials in Endocrine disorders in Switzerland (PO)
  • 15 Feb 2017 Damian Pharma plans a phase I trial for Endocrine disorders (In volunteers) in United Kingdom (NCT03046589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top